I agree about getting back to the bread and butter BoM2 ... years of research, evolving knowledge, demonstrated positive impact, BTD, huge market, etc.

I think the Covid "distraction" represented (and maybe still does) a quicker path to approval, or EUA given the world wide interest and impact. Once proven safe and effective, it might have become easier and quicker to get more indications approved, or even used off label and moved toward EUA in other areas upon successes. Covid may be a quicker and less expensive path for a cash strapped company, but BoM2 seems like a surer bet if cash/time are not as critical. Not sure, just some thoughts.

Whether Covid, or BoM2, I do feel a little better again about interest and effort going into ABL, hopefully, given this new extension rather than Hepa applying a boot to the throat for $6m cash or the IP.  

Fingers crossed for something big and promising coming in the near future.